News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

DelMar Pharmaceuticals and Guangxi Wuzhou Pharma Form Advisory Board for Cancer Drug


9/10/2013 9:03:18 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

by Richard Daverman, PhD

September 9, 2013 -- DelMar Pharma and Guangxi Wuzhou Pharma have formed a China clinical advisory board to oversee trials of their cancer treatment, which is known as VAL-083 or "DAG for Injection." The drug is already approved in China for leukemia and lung cancer. The two companies are working together to gain China approval for VAL-083 as a treatment for glioblastoma multiforme, the most aggressive form of brain cancer, and global approval for all indications. More details....

Stock Symbol: (OTCQB: DMPI)

Help employers find you! Check out all the jobs and post your resume.

Read at ChinaBio Today

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES